Browsing Tag
Pancreatic Cancer
38 posts
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates?
Amplia’s pancreatic cancer trial hits a 31% response rate, surpassing MPACT. Find out how it compares to POLO and what it means for future therapy options.
Understanding pancreatic cancer: causes, symptoms, tests, and treatments explained
Learn everything about pancreatic cancer in this comprehensive guide—what causes it, how it develops, signs to watch for, diagnostic methods, and current treatment options.
Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit
Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline.
Zai Lab and Novocure’s TTFields therapy shows survival benefit in pancreatic cancer: PANOVA-3 results unveiled at ASCO 2025
Zai Lab and Novocure report TTFields improves survival in pancreatic cancer. Read how ASCO 2025 results could reshape the standard of care.
Silexion Therapeutics’ SIL204 emerges as a potential game-changer in KRAS-driven cancer treatment
Silexion Therapeutics (NASDAQ: SLXN) has taken a major step forward in oncology research, unveiling new preclinical data on…
TME Pharma expands AI-driven drug discovery with Aimed Analytics partnership
TME Pharma, a biotechnology company pioneering therapies that target the tumor microenvironment, has announced a strategic collaboration with…
Silexion Therapeutics’ SIL-204 shows potential to transform pancreatic cancer treatment
Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company specializing in RNA interference (RNAi) therapies, has reported promising…
Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment
Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its…
Oncolytics Biotech advances pancreatic cancer study following regulatory approval
Oncolytics Biotech has achieved a critical milestone in its efforts to transform pancreatic cancer treatment, with Germany’s Paul-Ehrlich-Institute…